ICICI Direct: Dabur India Q2 - Strong Tailwinds For Health, Ayurveda Products
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Dabur India Ltd. witnessed splendid domestic volume growth of 16.8% led by immunity boosting, ayurveda and naturals product portfolio.
Consolidated revenue grew 13.7% led by strong 17.9% growth in India business.
International business saw muted growth on account of sluggish sales in Middle East and North Africa region.
The company is one of the biggest beneficiary of increased health awareness in a post-Covid-19 world.
Chyawanprash, honey, over-the-counter and ethical products, oral care witnessed robust growth during the quarter.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.